Scholarlink

<p>Community-acquired pneumonia (CAP) remains a major global health burden, with antibacterial therapy as the primary treatment strategy. In clinical practice, plasma drug concentrations are often used to guide therapy, yet they may not reliably reflect effective pulmonary exposure, which is particularly critical for older adults, patients with comorbidities, and critically ill populations. In recent years, targeted pulmonary pharmacokinetics/pharmacodynamics (PK/PD) studies have gained increasing attention and have become an important reference for guiding precision antimicrobial therapy in clinical settings. This review provides a comprehensive overview of the pulmonary PK characteristics of key antibiotics commonly used for CAP, including macrolides, fluoroquinolones, β-lactams, tetracyclines, and the pleuromutilin agent lefamulin. Major factors influencing drug distribution in the lung are summarized. The significance of pulmonary PK/PD targets in antibiotic selection, dose adjustment, and individualized treatment is discussed, aiming to support improved clinical outcomes, rational antibiotic use, and resistance management. A deeper understanding of pulmonary PK/PD properties is essential to advance evidence-based and optimized treatment for CAP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pulmonary Pharmacokinetics/Pharmacodynamics of Commonly Used Antibiotics in the Treatment of Community-Acquired Pneumonia

  • 期刊论文

  • 发表日期：

    2026年6月2日

查看全文
  • Yimin Wang,
  • Jiankang Zhao,
  • Bin Cao

摘要

Community-acquired pneumonia (CAP) remains a major global health burden, with antibacterial therapy as the primary treatment strategy. In clinical practice, plasma drug concentrations are often used to guide therapy, yet they may not reliably reflect effective pulmonary exposure, which is particularly critical for older adults, patients with comorbidities, and critically ill populations. In recent years, targeted pulmonary pharmacokinetics/pharmacodynamics (PK/PD) studies have gained increasing attention and have become an important reference for guiding precision antimicrobial therapy in clinical settings. This review provides a comprehensive overview of the pulmonary PK characteristics of key antibiotics commonly used for CAP, including macrolides, fluoroquinolones, β-lactams, tetracyclines, and the pleuromutilin agent lefamulin. Major factors influencing drug distribution in the lung are summarized. The significance of pulmonary PK/PD targets in antibiotic selection, dose adjustment, and individualized treatment is discussed, aiming to support improved clinical outcomes, rational antibiotic use, and resistance management. A deeper understanding of pulmonary PK/PD properties is essential to advance evidence-based and optimized treatment for CAP.